The initial reporter stated they received discrepant results for three patient samples tested with the elecsys anti-hav gen.2 assay on a cobas pro e 801 module.Samples 2 and 3 also had discrepant results when tested on a cobas 8000 e 801 module at a second site.No incorrect results were reported outside of the laboratory.The reporter states that samples that are (b)(6) with the elecsys anti-hav gen.2 assay will always have cutoff index values around (b)(6) values will always be around (b)(6) and never more than (b)(6).These values are very close to the cutoff of the assay (b)(6).The first sample resulted with an (b)(6) when tested on the customer's cobas pro e 801 analyzer on (b)(6) 2020.This sample was repeated on the customer's e 801 analyzer on (b)(6) 2020, resulting with (b)(6).The sample was sent to another laboratory for testing on an abbott architect analyzer, resulting with (b)(6).The second sample resulted with an (b)(6) when tested on the customer's e 801 analyzer on 27-nov-2020.The sample was repeated on the customer's e 801 analyzer on (b)(6) 2020, resulting with (b)(6).The sample was sent to another laboratory for testing on a cobas 8000 e 801 analyzer, resulting with (b)(6).When sent to another site for testing on an abbott architect analyzer, this sample resulted with a (b)(6).The third sample resulted with an (b)(6) when tested on the customer's e 801 analyzer on (b)(6) 2020.The sample was repeated on the customer's e 801 analyzer on (b)(6) 2020, resulting with a (b)(6).The sample was sent to another laboratory for testing on a cobas 8000 e 801 analyzer, resulting with a (b)(6).When sent to another site for testing on an abbott architect analyzer, this sample resulted with a (b)(6).The serial number of the customer's e 801 analyzer is (b)(4).
|
The reporter stated they received discrepant elecsys anti-hav gen.2 results for two additional patient samples (samples 4 and 5).It is unknown if any incorrect results were reported outside of the laboratory for samples 4 and 5.The abbott architect data provided in the initial medwatch is for the abbott anti-hav igg assay.For samples 2-5, the reporter has provided additional measurements.Refer to the attachment for a summary of all values that were provided, including those initially reported.Samples 2-5 were repeated again using the following methods: the elecsys anti-hav gen.2 assay on the customer's e 801, the elecsys anti-hav (gen.1 quantitative assay) on the e 801 analyzer at the second site, an unknown anti-hav igm assay at the customer site, and an abbott anti-hav igm assay.
|